pomalidomide has been researched along with glycine in 8 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (glycine) | Trials (glycine) | Recent Studies (post-2010) (glycine) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 35,163 | 756 | 8,415 |
| Protein | Taxonomy | pomalidomide (IC50) | glycine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.4852 | |
| Sodium- and chloride-dependent glycine transporter 1 | Homo sapiens (human) | 106 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Sodium- and chloride-dependent glycine transporter 2 | Homo sapiens (human) | 128 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, CK; Jung, Y; Kang, SW; Kim, BG; Kim, TH; Lee, SE; Lim, JY; Min, CK; Park, E; Park, J; Won, KA | 1 |
| Boccadoro, M; Bonello, F; Larocca, A; Salvini, M | 1 |
| Costello, C; Mikhael, JR | 1 |
| Joseph, NS; Kaufman, JL | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM | 1 |
| Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A | 1 |
3 review(s) available for pomalidomide and glycine
| Article | Year |
|---|---|
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Survival Rate; Thalidomide | 2017 |
Novel Approaches for the Management of AL Amyloidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Magnetic Resonance Imaging; Prognosis; Thalidomide | 2018 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
2 trial(s) available for pomalidomide and glycine
| Article | Year |
|---|---|
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2021 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Thalidomide | 2022 |
3 other study(ies) available for pomalidomide and glycine
| Article | Year |
|---|---|
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycine; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Thalidomide; Xenograft Model Antitumor Assays | 2016 |
Therapy sequencing strategies in multiple myeloma: who, what and why?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Thalidomide | 2018 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |